CASE REPORTS
Year : 2022 | Volume
: 13 | Issue : 3 | Page : 314--316
Serious adverse effects following use of liraglutide in individuals with type 2 diabetes
Benjamin M Easow, Milly Mathew, Urjitha Rajagopalan, P Nagarajan, Georgi Abraham
MGM Healthcare, No. 72 Nelson Manickam Road, Chennai 600029, Tamil Nadu, India
Correspondence Address:
Prof. Georgi Abraham
Department of Nephrology, MGM Healthcare, No. 72 Nelson Manickam Road, Chennai 600029, Tamil Nadu
India
Glucagon-like peptide-1 (GLP-1) analog liraglutide is extensively used for type 2 diabetes mellitus, especially in those with overweight and cardiovascular risk factors. The risk benefit ratio favors their use. The life-threatening complications such as cholecystitis and pancreatitis are infrequently reported. Here we report two patients who developed recurrent gallstone diseases with cholestatic jaundice and acute pancreatitis in a male patient and an asymptomatic large gallstone stone in a female kidney transplant patient with no previous evidence of gallstone disease. This highlights the importance of surveillance screening in patients on liraglutide to prevent the development of complications.
How to cite this article:
Easow BM, Mathew M, Rajagopalan U, Nagarajan P, Abraham G. Serious adverse effects following use of liraglutide in individuals with type 2 diabetes.J Diabetol 2022;13:314-316
|
How to cite this URL:
Easow BM, Mathew M, Rajagopalan U, Nagarajan P, Abraham G. Serious adverse effects following use of liraglutide in individuals with type 2 diabetes. J Diabetol [serial online] 2022 [cited 2023 Feb 4 ];13:314-316
Available from: https://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2022;volume=13;issue=3;spage=314;epage=316;aulast=Easow;type=0 |
|
|
|
